Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B

Bonino, F.; Marcellin, P.; Lau, G. K. K.; Hadziyannis, S.; Jin, R.; Piratvisuth, T.; Germanidis, G.; Yurdaydin, C.; Diago, M.; Gurel, S.; Lai, M.-Y.; Brunetto, M. R.; Farci, P.; Popescu, M.; McCloud, P.
May 2007
Gut;May2007, Vol. 56 Issue 5, p699
Academic Journal
Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon α-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated. Methods: Multivariate analyses were performed using available data from 518 patients treated with peginterferon α-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of <20 000 copies/ml. Results: In logistic regression analyses across all treatment arms, peginterferon α-2a (with or without lamivudine) therapy, younger age, female gender, high baseline ALT, low baseline HBV DNA and HBV genotype were identified as significant predictors of combined response at 24 weeks post-treatment. In the peginterferon α-2a and lamivudine monotherapy arms, patients with genotypes B or C had a higher chance of response than genotype D infected patients (p<0.001), the latter responding better to the combination than to peginterferon α-2a monotherapy (p = 0.015). At 1 year post-treatment, response rates by intention-to-treat analysis were 19.2% for the peginterferon α-2a, 19.0% for the combination, and 10.0% for the lamivudine groups, with genotypes B or C associated with a sustained combined response to peginterferon α-2a with or without lamivudine therapy. Conclusions: Baseline ALT and HBV DNA levels, patient age, gender, and infecting HBV genotype significantly influenced combined response at 24 weeks post-treatment, in patients treated with peginterferon α-2a and/or lamivudine. At 1 year post-treatment HBV genotype was significantly predictive of efficacy for patients treated with peginterferon α-2a with or without lamivudine.


Related Articles

  • The loss of HBeAg without precore mutation results in lower HBV DNA levels and ALT levels in chronic hepatitis B virus infection. Kawabe, Naoto; Hashimoto, Senju; Harata, Masao; Nitta, Yoshifumi; Murao, Michihito; Nakano, Takuji; Shimazaki, Hiroaki; Arima, Yuko; Komura, Naruomi; Kobayashi, Kyoko; Yoshioka, Kentaro // Journal of Gastroenterology;2009, Vol. 44 Issue 7, p751 

    The aim of this study was to investigate the correlation between precore (PC)/basal core promoter (BCP) mutations and the viral loads or activity of hepatitis in patients with chronic hepatitis B virus (HBV) infection. HBV genotypes, PC mutations, BCP mutations, HBV DNA levels, and serological...

  • Current and Novel Therapies for Hepatitis B Virus Infection. Sato, K.; Mori, M. // Mini Reviews in Medicinal Chemistry;Jan2010, Vol. 10 Issue 1, p20 

    Many therapeutic reagents for hepatitis B virus infection have established efficacy in goals such as alanine aminotransferase normalization, hepatitis B virus DNA suppression, HBeAg seroconversion, histological improvement, and reduce disease progression. However, it is not established that the...

  • Invasive pulmonary aspergillosis in patients with HBV-related liver failure. Wang, W.; Zhao, C. Y.; Zhou, J. Y.; Wang, Y. D.; Shen, C.; Zhou, D. F.; Yin, H. Z. // European Journal of Clinical Microbiology & Infectious Diseases;May2011, Vol. 30 Issue 5, p661 

    Invasive pulmonary aspergillosis (IPA) has been increasingly frequent in severe liver disease. We aim to investigate the clinical presentation, predisposing factors, and treatment of IPA in patients with liver failure caused by hepatitis B virus (HBV) infection. Medical records from 798 patients...

  • Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Chan, H. L.-Y.; Hui, A. Y.; Wong, M. L.; Tse, A. M.-L.; Hung, L. C.-T.; Wong, V. W.-S.; Sung, J. J.-Y. // Gut;Oct2004, Vol. 53 Issue 10, p1494 

    Background: Identification of risk factors for the development of hepatocellular carcinoma (HCC) is important for HCC surveillance in chronic hepatitis B virus (HBV) infection. Our aim was to study the independent risk factors and effect of HBV genotypes on HCC development in a prospective...

  • Predicting Relapse after Cessation of Lamivudine Monotherapy for Chronic Hepatitis B Virus Infection. Ito, Kiyoaki; Tanaka, Yasuhito; Onto, Etsuro; Hirashima, Noboru; Ide, Tatsuya; Hino, Teruko; Kumashiro, Ryukichi; Kato, Atunaga; Nukaya, Haruhiko; Sakakibara, Kenji; Mukaide, Motokazu; Ito, Hidemi; Sata, Michio; Ueda, Ryuzo; Mizokami, Masashi // Clinical Infectious Diseases;2/15/2004, Vol. 38 Issue 4, p490 

    There have been reports of relapse after cessation of lamivudine monotherapy for hepatitis B virus (HBV) infection. The aim of this study was to examine factors that predict posttreatment relapse. Comparison 22 patients who experienced relapse with 11 who did not after cessation of therapy...

  • Adefovir dipivoxil monotherapy is a sufficiently effective treatment modality for Japanese patients with lamivudine-resistant chronic hepatitis B. Sato, Ken; Takagi, Hitoshi; Kakizaki, Satoru; Sohara, Naondo; Mori, Masatomo // Journal of Gastroenterology;Mar2006, Vol. 41 Issue 3, p283 

    The article presents a study to evaluate the efficacy of adefovir dipivoxil monotherapy for Japanese patients with lamivudine-resistant chronic hepatitis B. The study found that the alanine aminotransferase level in all the patients under observation decreased and normalized in 67 percent...

  • The Natural History and Treatment of Chronic Hepatitis B: A Critical Evaluation of Standard Treatment Criteria and End Points. Ching-Lung Lai; Man-Fung Yuen // Annals of Internal Medicine;7/3/2007, Vol. 147 Issue 1, p58 

    The definite indications for the treatment of chronic hepatitis B are serum hepatitis B virus (HBV) DNA levels greater than 105 copies/mL and alanine aminotransferase (ALT) levels more than 2 times the upper limit of normal. If cirrhosis is present, an HBV DNA level greater than 105 copies/mL is...

  • Significance of blood-related high-risk behaviors and horizontal transmission of hepatitis B Virus in Iran. Abedi, Farshid; Madani, Hossain; Asadi, A.; Nejatizadeh, Azim // Archives of Virology;Apr2011, Vol. 156 Issue 4, p629 

    Hepatitis B virus (HBV) is a significant public health problem and a leading cause of morbidity and mortality, and approximately 30% of the world's population is infected with HBV. The objective of our study was to determine the seroprevalence of HBV and major risk factors associated with its...

  • Temporal relationship between hepatitis B virus enhancer II/basal core promoter sequence variation and risk of hepatocellular carcinoma. Chou, Y-C; Yu, M-W; Wu, C-F; Yang, S-Y; Lin, C-L; Liu, C-J; Shih, W-L; Chen, P-J; Liaw, Y-F; Chen, C-J // Gut;Jan2008, Vol. 57 Issue 1, p91 

    Background and aims: To investigate the temporal relationship between sequence variation in the enhancer II (EnhII), basal core promoter (BCP), and precore regions of hepatitis B virus (HBV) and the risk of hepatocellular carcinoma (HCC), we conducted a nested case-control study within a cohort...


Read the Article


Sign out of this library

Other Topics